Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
For the three months ended September 30, 2026, CCO Holdings reported a consolidated net loss of $3.512 billion, primarily driven by a $6.326 billion impairment of franchises. Despite the loss, revenues grew to $14.922 billion compared to $13.672 billion in the prior year period, while total assets increased significantly to $176.331 billion following the Cox Transactions.
Treace Medical Concepts, Inc. filed this Form 10-Q for the quarter ended September 30, 2026, reporting 65,559,597 shares of common stock outstanding as of October 30, 2026. The company is focused on managing expenses to offset revenue growth shifts and navigating competition in the bunion surgery market, including its flagship Lapiplasty system.
E.W. Scripps reported Q3 2026 revenue of $545 million and net income of $20.7 million, driven by record political advertising revenue which reached $284 million for the full year. The company is executing a transformation plan that has reduced its workforce by 20% and is expected to generate $125-$150 million in EBITDA growth by 2028. Management plans to use cash from political advertising to pay down at least $150 million of debt in the fourth quarter.
Term
Q3 2026
“During this contentious 2026 midterm election cycle, broadcast television continued to prove itself to be the best vehicle for reaching voters because we provide a trustworthy platform in a politically polarizing climate.”
Adam Symson, President and CEO
“The companywide transformation we launched in February is well underway and on track to deliver both on our commitment to evolve the company’s products and the expected benefit to enterprise EBITDA next year.”
Canopy Growth reported Q2 FY2027 consolidated net revenue of $81.4M, a 22% year-over-year increase driven by 141% growth in international markets. The company saw strong performance in its cannabis segment, particularly in Germany and Poland, and is targeting positive adjusted EBITDA during fiscal 2027.
Term
Q2 2027
“We have made tremendous progress on our international strategy. Our international business delivered 141% net revenue growth in the second quarter of fiscal year 2027 driven by strong medical cannabis sales in Germany and Poland.”
Luc Mongeau, Chief Executive Officer
“We reported another quarter of strong net revenue growth, including a 17% year-over-year increase in Canada adult-use cannabis, an 18% increase in Canada medical cannabis and 30% growth in the Cannabis segment overall. We are progressing steadily to profitability, quarter after quarter.”
For the thirty-nine weeks ended September 27, 2026, Bloomin' Brands reported total revenues of $3.02 billion and net income attributable to the company of $84.8 million, a significant increase from $21.7 million in the prior year period. The company's balance sheet shows total assets of $3.13 billion and a reduction in total liabilities to $2.70 billion compared to year-end 2025.
Enbridge Inc. reported total operating revenues of $21,077 million for the third quarter of 2026, a significant increase from $14,639 million in the prior year, primarily driven by higher commodity sales. Earnings attributable to common shareholders rose to $1,288 million ($0.59 per share) for the quarter, compared to $682 million ($0.30 per share) in 2025, reflecting strong operational performance despite higher commodity and operating costs.
Treace Medical Concepts reported Q3 2026 revenue of $48.3 million, a 4% decrease year-over-year primarily due to a shift toward lower-priced minimally invasive products. Despite the revenue dip, the company improved its net loss by 23% to $12.6 million and achieved positive Adjusted EBITDA of $0.3 million through targeted expense reduction initiatives.
Term
Q3 2026
“We are encouraged by our third quarter performance, reflecting accelerated double-digit case volume growth and continued market share gains – driven by increasing adoption of our comprehensive range of best-in-class bunion systems, as well as our expanding portfolio of new technologies including our SuperBite™ compression screws.”
John T. Treace, CEO and Chairman of Treace Medical
“We continue to make disciplined investments in key growth initiatives with an emphasis on our product pipeline, while staying focused on improving profitability and reducing cash usage. We believe this balanced approach positions us to build momentum and deliver stronger growth to finish the year.”
John T. Treace, CEO and Chairman of Treace Medical
Optimum Communications reported a significant net loss of $5.34 billion for the nine months ended September 30, 2026, primarily driven by $6.36 billion in restructuring and impairment charges. Total assets decreased from $30.7 billion to $24.7 billion, largely due to a $5.9 billion write-down of indefinite-lived cable franchise rights.
Fluor Corporation reported third quarter 2026 revenue of $3.7 billion and record quarterly new awards of $10.9 billion, driven by LNG Canada Phase 2 and mining projects. The company's backlog reached a decade-high of $34.3 billion, while it also completed $300 million in share repurchases during the quarter.
Term
Q3 2026
“Our third quarter results reflect strong demand across our key markets and continued progress converting our prospect pipeline into high-quality awards. New awards of $10.9 billion, including LNG Canada Phase 2 as well as two mining projects, was the highest quarterly total in Fluor’s history and grew backlog 21% to $34.3 billion, building a solid foundation for sustained growth.”
Essent Group reported Q3 2026 net income of $163.4 million, or $1.82 per diluted share, supported by a mortgage insurance portfolio of $250.1 billion. The company also declared a quarterly dividend of $0.35 per share and announced a new $500 million share repurchase authorization effective through 2028.
Term
Q3 2026
“Our third quarter results reflect the earnings power of our mortgage insurance and reinsurance franchise. With the solid credit quality of our insurance in force and our strong capital position, we are well positioned to deliver high-quality earnings with continued flexibility to invest in the business and return capital to shareholders.”
Mark A. Casale, Chairman and Chief Executive Officer
DraftKings reported a net loss of $468.7 million for the quarter ended September 30, 2026, on revenue of $1.33 billion, reflecting significant increases in sales and marketing expenses. The company's balance sheet shows a shift in debt structure with a decrease in convertible notes and an increase in Term B Loans, while total stockholders' equity declined to $179.6 million.
TeraWulf reported Q3 2026 financial results, highlighted by $76.2 million in revenue, of which 83% was driven by HPC lease revenue. The company reported a significant net income of $709.9 million, primarily due to a non-cash change in the fair value of warrants, and ended the quarter with $2.4 billion in cash. Key strategic progress includes a 20-year, $19 billion lease agreement with Anthropic and the expansion of contracted power at the Muskie campus to 1 GW.
AirSculpt Technologies reported a net loss of $7.2 million for the third quarter of 2026, an improvement from a $9.5 million loss in the prior year period, despite a revenue decline to $31.9 million. The company strengthened its balance sheet through an equity issuance, increasing common stock outstanding to 73.9 million shares and reducing long-term debt to $31.2 million.
Charter Communications reported a consolidated net loss of $2.7 billion for the third quarter of 2026, primarily driven by a $6.3 billion impairment of franchises. Despite the net loss, revenues grew to $14.9 billion for the quarter compared to $13.7 billion in the prior year, while the company navigated significant structural changes including the Cox and Liberty Broadband transactions.
Ubiquiti Inc. reported strong growth for the first quarter of fiscal 2027, with revenues increasing to $1.03 billion from $733.8 million in the prior year period. Net income rose significantly to $320.5 million, or $5.29 per diluted share, driven by higher sales volume and improved gross margins of 47.3%.
Vistra Corp. reported third quarter 2026 net income of $1,140 million and Ongoing Operations Adjusted EBITDA of $2,378 million, representing over 50% year-over-year growth. The company raised its 2026 EBITDA guidance and initiated 2027 guidance, while the board authorized an additional $1.5 billion share repurchase program to be utilized by 2028.
“I am proud of the results the Vistra team delivered this quarter. Through one of the hottest calendar third quarters on record, our generation team kept the fleet running safely and reliably while our retail team delivered for our customers. At the same time, our people moved forward a significant amount of commercial and development work. I want to thank each one of our team members for their hard work and dedication - it's what truly sets Vistra apart.”
Jim Burke, president and CEO of Vistra
“We also made significant progress on our growth strategy this quarter. We began commercial operations at our Pulaski and Deer Creek facilities, and signed a 20-year agreement with New Era at our Odessa plant. As the power landscape evolves, we continue to see more of these opportunities. Our team remains focused on delivering safe, reliable, and affordable electricity to our customers, and we look forward to finishing the year strong.”
Enbridge reported Q3 2026 GAAP earnings of $1.3 billion and adjusted EBITDA of $4.4 billion, while reaffirming its full-year 2026 financial guidance. The company highlighted significant strategic activity, including the $2.6 billion acquisition of Tallgrass Energy's crude business and the placement of $3 billion in gas transmission projects into service. Management noted that energy demand from AI infrastructure and manufacturing is driving growth in their $38 billion secured project backlog.
Term
Q3 2026
“The global focus on energy security, reliability and affordability continues to reinforce the value of Enbridge’s strategically positioned infrastructure. Our scale, connectivity, diversified asset base, and all-of-the-above approach to energy investment position us to serve growing energy demand while delivering predictable, long-term value for customers and shareholders.”
Greg Ebel, President and CEO
“As energy demand accelerates, driven by AI infrastructure, advanced manufacturing and broader economic growth, our integrated networks are increasingly important to providing the reliable, affordable energy our customers require. That opportunity continues to translate into visible growth across our businesses.”
Glaukos Corporation filed a formal investor presentation dated November 2026 to be used in meetings with investors and stakeholders. The presentation covers the company's strategic outlook, including the commercialization of its iDose TR and Epioxa therapies.
Charter Communications reported third quarter 2026 financial results and announced a new operating model following its acquisition of Cox Communications. The company is targeting $2 billion in annualized operating expense savings over the next 18 months to drive efficiency and return to internet customer growth.
Term
Q3 2026
“With the combination of Charter and Cox, we have the scale and network capabilities to connect more Americans than ever before. We are America’s Internet Company® and our purpose is Connecting Gigabit America. Today, we are announcing decisive steps to unlock our full potential.”
Chris Winfrey, President and CEO of Charter
“We are fundamentally rethinking how we operate and compete, with a renewed focus on delivering the best products and services. We will return Charter to Internet customer growth and transform Charter into a simpler, faster, more agile organization – and reignite our culture to win.”
Perspective Therapeutics announced incremental Phase 1/2a clinical trial data for [212Pb]VMT-α-NET in patients with advanced neuroendocrine tumors (NETs). The data, presented at the NANETS 2026 Symposium, showed a 75% progression-free survival rate at 18 months and a 47% response rate in Cohort 3, supporting plans for a Phase 3 study initiation in 2027.
Precision BioSciences priced an underwritten public offering of approximately 10.2 million shares and 5.9 million pre-funded warrants for gross proceeds of $125 million. The offering included participation from several life sciences investors including First Light Asset Management and MPM BioImpact. Proceeds will fund research and development for PBGENE-HBV and PBGENE-DMD programs.
Innovative Industrial Properties filed Articles Supplementary to increase the number of authorized shares of its 9.25% Series B Cumulative Redeemable Preferred Stock by 16.1 million shares. This brings the total authorized and classified Series B Preferred Stock to 18.4 million shares. The filing notes that as of the date of the report, no shares have been issued or sold under this new authorization.
Starwood Property Trust reported a net loss of $389.7 million for the third quarter of 2026, primarily driven by a significant $336.6 million credit loss provision and $121.6 million in fair value losses on mortgage loans. Despite these losses, total revenues grew to $545.9 million compared to $488.9 million in the prior year, supported by increased interest income and rental income.
AirSculpt Technologies reported Q3 2026 revenue of $31.9 million and a net loss of $7.2 million, while lowering its full-year 2026 revenue guidance to $144M-$146M. The company also announced a new $39 million senior secured term loan with Blue Torch Finance to refinance existing debt and extend its maturity to 2031.
“While our third quarter results were below expectations, we identified the key drivers and are addressing them with a sense of urgency. Importantly the quarter saw strong progress on our priorities, including expanding our GLP-1-related procedures. Following quarter end, we marked a key milestone as we completed the refinance of our term loan - extending our debt maturity to 2031. While we have reduced our guidance to reflect our third quarter performance continuing through year-end, we remain confident in our strategy and our ability to deliver sustainable, profitable long-term growth.”
Starwood Property Trust reported a GAAP net loss of $389.7 million for Q3 2026, primarily driven by a $336.6 million credit loss provision. Despite the loss, the company deployed $3.2 billion in capital during the quarter, including $2.4 billion in commercial lending, and repurchased $108 million of its own common shares.
Term
Q3 2026
“The third quarter of the year was somewhat historic. Interest rates skyrocketed and the forward yield curve moved sharply higher. Though the real estate markets continued their healing, bolstered by a meaningful collapse in most all major asset classes, the rise in rates sent a bit of a shock wave through the property sector and related rate sensitive sectors. We held steady and continued to make meaningful investments in the quarter while continuing to resolve our underperforming assets and loans.”
Barry Sternlicht, Chairman and CEO
“We took advantage of favorable market conditions earlier this year, before the significant rate rise, to proactively refinance and extend our corporate debt. We completed approximately $2.1 billion of financing transactions at rates and spreads below those available today. We continue to be even more vigilant in the deployment of capital across our diversified businesses, including investing in our own shares, purchasing a record $108 million in the quarter, as we focus on the most attractive risk-adjusted returns.”
AirSculpt Technologies reported third quarter 2026 revenue of $31.9 million, an 8.7% decline year-over-year, and a net loss of $7.2 million. The company also announced a $39.0 million term loan refinancing with Blue Torch Finance to extend its debt maturity to 2031 and lowered its full-year 2026 revenue guidance.
“While our third quarter results were below expectations, we identified the key drivers and are addressing them with a sense of urgency. Importantly the quarter saw strong progress on our priorities, including expanding our GLP-1-related procedures. Following quarter end, we marked a key milestone as we completed the refinance of our term loan - extending our debt maturity to 2031. While we have reduced our guidance to reflect our third quarter performance continuing through year-end, we remain confident in our strategy and our ability to deliver sustainable, profitable long-term growth.”
DraftKings reported Q3 2026 revenue of $1.33 billion, a 16% year-over-year increase driven by strong customer engagement and higher sportsbook margins. The company introduced FY2027 revenue guidance of $7.35 billion to $7.75 billion and updated its FY2026 Adjusted EBITDA outlook to reflect increased investment in its new Predictions offering.
Term
Q3 2026
“The third quarter marked a pivotal moment for DraftKings, as the Predictions offering we have been building is now powering meaningful growth for our business. More than 1.6 million customers have engaged with Predictions year-to-date, and combined with the strength of our core, we believe we are set up for an exceptional 2027.”
Jason Robins, DraftKings’ Chief Executive Officer and Co-founder
“Our core business continues to generate significant free cash flow, which we are deploying to fund growth in our Predictions business at attractive payback periods. We are introducing fiscal year 2027 revenue guidance of $7.35 billion to $7.75 billion, an increase of 17% year-over-year at the midpoint, and Adjusted EBITDA guidance of $800 million to $1.0 billion, which includes $300 million of Adjusted EBITDA investment in Predictions at the midpoint.”
Alan Ellingson, DraftKings’ Chief Financial Officer
Moderna reported Q3 2026 revenue of $1.3 billion, a 29% increase year-over-year, and achieved GAAP net income of $162 million. The company raised its full-year 2026 revenue growth guidance to 15%–25% and highlighted the U.S. FDA approval of mFLUSIVA, its fifth approved product globally.
Term
Q3 2026
“We delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive Phase 3 results for intismeran in melanoma.”
Stéphane Bancel, Chief Executive Officer of Moderna
“Building on this momentum, we increased our full-year revenue growth outlook to 15%-25%, while continuing to reduce costs and strengthen our balance sheet. Looking ahead, we anticipate additional intismeran readouts, pivotal data in propionic acidemia and further regulatory approvals as we advance our pipeline and build a more diversified company.”
Stéphane Bancel, Chief Executive Officer of Moderna
Vogenx reported Q3 2026 financial results, its first as a public company following a $93.4 million IPO in August. The company ended the quarter with $82.1 million in cash and initiated its Phase 2b EMERGE study for mizagliflozin in post-bariatric hypoglycemia.
Term
Q3 2026
“Our third quarter performance marks a pivotal milestone for Vogenx following our successful public listing in August. The EMERGE study is now up and running and we have added critical headcount across the Company, positioning us to advance the development of mizagliflozin for both post-bariatric hypoglycemia (PBH) and gastroparesis.”
Bowman Consulting Group Ltd. filed its Q3 2026 10-Q reporting 17,535,662 shares of common stock outstanding as of November 4, 2026. The filing highlights a pending merger with Bernhard Capital Partners and notes the upcoming retirement of CEO Gary Bowman, while identifying risks related to international hostilities, inflation, and acquisition integration.